Granules Pharmaceuticals Inc. secured FDA approval for its Abbreviated New Drug Application of methylphenidate hydrochloride tablets, unlocking a significant revenue opportunity in the ADHD therapeutics market. This launch is poised to increase competitive pressure against branded products and drive price competition within the generic segment.